within Pharmacolibrary.Drugs.ATC.M;

model M04AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.007833333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Benzbromarone is a uricosuric agent formerly used to treat gout and hyperuricemia by increasing renal excretion of uric acid. Due to concerns regarding hepatotoxicity, its approval is withdrawn or limited in many countries, but it is still available in some regions for gout patients intolerant to other treatments.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Uchida, S, et al., &amp; Watanabe, H (2010). Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. <i>Drug metabolism and pharmacokinetics</i> 25(6) 605–610. DOI:<a href=&quot;https://doi.org/10.2133/dmpk.dmpk-10-nt-040&quot;>10.2133/dmpk.dmpk-10-nt-040</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20962433/&quot;>https://pubmed.ncbi.nlm.nih.gov/20962433</a></p></li><li><p>Zhao, Z, et al., &amp; Pang, J (2022). Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. <i>European journal of medicinal chemistry</i> 242 114682–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejmech.2022.114682&quot;>10.1016/j.ejmech.2022.114682</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36001935/&quot;>https://pubmed.ncbi.nlm.nih.gov/36001935</a></p></li><li><p>Ferber, H, et al., &amp; Hitzenberger, G (1981). Pharmacokinetics and biotransformation of benzbromarone in man. <i>European journal of clinical pharmacology</i> 19(6) 431–435. DOI:<a href=&quot;https://doi.org/10.1007/BF00548587&quot;>10.1007/BF00548587</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7250176/&quot;>https://pubmed.ncbi.nlm.nih.gov/7250176</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M04AB03;
